← All trials
NCT06281834
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 30, 2024
- Primary completion
- Feb 28, 2027
- Completion date
- Jun 30, 2027
- First posted
- Feb 28, 2024
- Last posted
- Aug 19, 2024
- Enrollment
- 25
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Harvard UniversityLead sponsor
- Harvard UniversityOfficial
- APIN Public Health InitiativesCollaborator
- University of Cape TownCollaborator
- Harvard UniversitySponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.